• Magneto-Piezoelectric Scaffolds for Infectious Bone Repair

  2026-09-11

  This ACS Nano study develops a dual-responsive scaffold that combines magnetic biofilm disruption with ultrasound-triggered metabolic reprogramming of Icam1+ macrophages. Its central mechanistic finding is that activating JAK2-STAT3 while suppressing MAPK-JNK restores oxidative phosphorylation and supports immune-assisted regeneration of infectious bone defects.

• Berbamine Hydrochloride in Ferroptosis Workflows

  2026-09-11

  Use Berbamine hydrochloride as a concentration-controlled perturbation tool to connect STAT3, calcium homeostasis, NF-κB activity, and ferroptosis-related phenotypes. This workflow separates pathway engagement from general cytotoxicity across leukemia cell line KU812 and hepatocellular carcinoma HepG2 cells.

• Recombinant Human EGF for 3D Spheroid Assays

  2026-09-10

  Use recombinant human EGF to tune EGFR-dependent growth conditions while measuring glioblastoma spheroid formation in a compact 96-well workflow. This guide combines product-handling guidance with a recent one-round tumor spheroid method, practical dose finding, and troubleshooting for separating proliferation from stemness.

• Morin Workflows for Oxidative Stress Research

  2026-09-10

  Morin supports complementary workflows for podocyte mitochondrial metabolism, AMPD activity, oxidative-stress biology, and aluminum-ion fluorescence. This practical guide connects assay design, formulation, controls, and troubleshooting while clearly separating bench research from clinical interpretation.

• ECL Chemiluminescent Substrate Detection Kit Workflow

  2026-09-09

  Build a sensitive, flexible western blot workflow for validating low-abundance metabolic and signaling proteins in diabetes research. This guide shows how hypersensitive HRP chemiluminescence, controlled exposure, and membrane-specific optimization can extend data from pathway-focused studies into reproducible immunoblot assays.

• Rosiglitazone in Beige Adipocyte Assay Design

  2026-09-09

  Rosiglitazone (Brl-49653) is more than a PPARγ adipogenesis control: it can help separate adipocyte differentiation from beige thermogenic maturation. This guide translates SEMA3E–β-catenin findings into a practical, mechanistically resolved assay strategy.

• Gemcitabine HCl: From Mechanism to MRI

  2026-09-08

  A translational strategy for connecting Gemcitabine HCl mechanism, cytotoxicity assays, dosing, and multianimal MRI in pancreatic cancer models.

• ECL Chemiluminescent Substrate Detection Kit

  2026-09-08

  The ECL Chemiluminescent Substrate Detection Kit (Enhanced), SKU K1230, is intended for sensitive HRP-based western blot chemiluminescence detection when low-abundance proteins or weak antibody signals are difficult to image. This dossier-based guide covers setup, imaging, quality control, and troubleshooting; it should not be treated as evidence for non-HRP assays or as a substitute for validating quantitative linearity in a specific experiment.

• BMS-777607 Workflows for c-Met Inhibition

  2026-09-07

  BMS-777607 is a potent c-Met inhibitor for dissecting MET-family signaling, metastatic behavior, and kinase-dependent phenotypes. This guide connects validated cancer assays with a clearly bounded exploratory workflow for hiPSC-derived megakaryocyte research.

• Rosiglitazone (Brl-49653): PPARγ Research Guide

  2026-09-07

  Rosiglitazone, also known as Brl-49653, is a synthetic thiazolidinedione PPARγ agonist used to study adipogenesis, glucose handling, and insulin sensitivity modulation. Its strongest research value is mechanistic: it connects PPARγ transcriptional activity with adipocyte biology, while its cancer and vascular findings remain preclinical.

• In Vitro Drug Response: Viability, Death, and Timing

  2026-09-05

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures in cancer drug studies. Its central contribution is a time-aware framework for distinguishing proliferative arrest from actual cell killing, improving interpretation of in vitro response data and the design of follow-up experiments.

• Phosphatase Inhibitor Cocktail 3: Practical Guide

  2026-09-04

  Phosphatase Inhibitor Cocktail 3 (100X in DMSO) helps limit dephosphorylation during extraction of animal tissues and cultured cells, supporting protein phosphorylation preservation for phosphoprotein analysis. It is intended for phosphorylation-sensitive sample preparation and downstream assays, not for measuring native phosphatase activity unless inhibitor carryover is specifically excluded or validated.

• ECL Chemiluminescent Substrate Detection Kit

  2026-09-04

  Improve western blot chemiluminescent detection when target proteins are scarce, antibody is limited, or longer imaging windows are valuable. This hypersensitive HRP substrate supports low-picogram immunoblotting on nitrocellulose and PVDF membranes with reduced background and a working reagent that remains usable for 24 hours.

• BML-277 and the Next Era of Chk2 Research

  2026-09-03

  BML-277 offers a precise way to interrogate Chk2-dependent DNA damage signaling, from T-cell radioprotection to emerging nuclear cGAS biology. This thought-leadership article connects biochemical potency with translational assay design while defining the evidence boundaries for applying Chk2 inhibition to genome stability and cancer research.

• Structure-Guided Proteomimetics Target SARS-CoV-2

  2026-09-03

  The reference study presents a structure-guided strategy for converting two hACE2 recognition elements into constrained proteomimetics that engage the SARS-CoV-2 Spike receptor-binding domain. Its lead compound, proteomimetic 28, disrupted the S-RBD/hACE2 interaction, reduced pseudovirus entry, and showed epithelial stability and low permeability that support further investigation of intranasal antiviral delivery.

8329 records 1/556 page Next 12345 下5页 Last page